Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.75 |
| ▸ | MAOA | P21397 | 2/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146711 | 1.00 | GOT1 (1.00) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| Hydrochloric Acid SCHEMBL2646490 | 0.98 | GOT1 (0.96) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| Dihydralazine SCHEMBL29484435 | 0.87 | ALDH1A1 (1.00) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| Dihydralazine SCHEMBL149629 | 0.87 | ALDH1A1 (1.00) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| SCHEMBL10876406 | 0.87 | GOT1 (0.75) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| Dihydralazine SCHEMBL3462832 | 0.82 | ALDH1A1 (0.90) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| SCHEMBL18454567 | 0.79 | GOT1 (0.66) | GOT1MAPTALDH1A1MAOAPTGS1 | |
| SCHEMBL29365992 | 0.79 | GOT1 (0.62) | GOT1MAPTALDH1A1MAOATDP1 | |
| SCHEMBL345211 | 0.79 | GOT1 (0.62) | GOT1MAPTALDH1A1MAOATDP1 | |
| SCHEMBL31306384 | 0.77 | GOT1 (0.62) | GOT1MAPTALDH1A1MAOAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660360-A | Application of 1-chloro-4-hydrazinophthalazine reactive matrix in monosaccharide MALDI MSI in-situ analysis | 中国科学院化学研究所 | 2023-08-29 | — | — | CN | claimed |
| US-20190298717-A1 | Hydralazine and Active Derivatives Thereof for Neuronal Cell Survival and Regeneration | UNIV TEXAS (US) | 2019-10-03 | — | — | US | claimed |
| WO-2017160864-A1 | HYDRALAZINE AND ACTIVE DERIVATIVES THEREOF FOR NEURONAL CELL SURVIVAL AND REGENERATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-21 | — | — | WO | claimed |
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-4559521-A2 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2025-05-28 | — | — | EP | disclosed |
| EP-4404931-B1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG AUGUST UNIV GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS UNIVSMEDIZIN (DE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119233820-A | Azo compounds for the treatment of fibrotic diseases | 乔治-奥古斯特-哥廷根公法基金会大学的大学医学院 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024227701-A1 | PYRIDAZINE COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Tietze Chemical Consulting UG (haftungsbeschränkt) (DE) | 2024-11-07 | — | — | WO | disclosed |
| EP-4458358-A1 | PYRIDAZINE COMPOUNDS FOR ANTIFIBROTIC THERAPY | Tietze Chemical Consulting UG (DE) | 2024-11-06 | — | — | EP | disclosed |
| EP-4404931-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin (DE) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023222865-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2000027849-A2 | THERAPEUTIC POLYMORPHS OF A GABA-A ALPHA-5 INVERSE AGONIST AND PAMOATE FORMULATIONS OF THE SAME | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0986562-A1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999043677-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PYRIDAZINE | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-02 | — | — | WO | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998050385-A1 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| US-4788186-A | ANXIOLYTIC AGENTS | GRUPPO LEPETIT S.P.A. (IT) | 1988-11-29 | — | — | US | disclosed |
| EP-0085840-B1 | NEW 6-SUBSTITUTED-S-TRIAZOLO(3,4-A)PHTHALAZINE DERIVATIVES | GRUPPO LEPETIT S.P.A. (IT) | 1986-10-01 | — | — | EP | disclosed |
| EP-0085840-A1 | New 6-substituted-s-triazolo(3,4-a)phthalazine derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298717-A1 | Hydralazine and Active Derivatives Thereof for Neuronal Cell Survival and Regeneration | GSK3B, MAPT, GSK3A | GOT1 543/4885MAPT 2/4885ALDH1A1 1374/4885 |
| US-20250215004-A1 | AZOLO COMPOUNDS FOR TREATMENT OF FIBROTIC DISEASES | COL1A1, COL14A1, COL2A1 | GOT1 474/4885MAPT 2369/4885ALDH1A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.